{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:50Z","timestamp":1786987610316,"version":"build-2736575974"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This monocentric study evaluated the real-world efficacy and safety of sonidegib in 17 patients with locally advanced (laBCC) or multiple (mBCC) basal cell carcinomas, characterized by complex surgical histories and comorbidities. The objective response was that 53% of patients achieved complete response, 29% partial response and 18% stable disease, with no documented progression during treatment (mean 7.3\u2005months). Sonidegib showed significant efficacy in mBCC, with a mean reduction of 3.89 lesions per patient. Key findings indicate that prior surgery correlates with poorer response, while sonidegib effectively \u2018clears the field\u2019 of subclinical lesions. The safety profile was favourable, with predominantly mild and manageable adverse events. Despite the limited sample size, our findings confirm the significant efficacy of sonidegib in a frail pretreated population with multiple comorbidities. This study supports the use of sonidegib as a valuable therapeutic strategy for complex patients with high tumour burden or those ineligible for further surgery.<\/jats:p>","DOI":"10.1093\/ced\/llag157","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:39:59Z","timestamp":1776944399000},"page":"1699-1703","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of sonidegib in locally advanced and multiple basal cell carcinomas: a monocentric prospective observational study"],"prefix":"10.1093","volume":"51","author":[{"given":"Chiara","family":"Del Re","sequence":"first","affiliation":[{"name":"Health Science Department, Magna Graecia University , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Filastro","sequence":"additional","affiliation":[{"name":"Health Science Department, Magna Graecia University , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Fasano","sequence":"additional","affiliation":[{"name":"Dermatology Complex Unit, Dulbecco University Hospital, Pugliese Ciaccio Hospital , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Valenti","sequence":"additional","affiliation":[{"name":"Dermatology Complex Unit, Dulbecco University Hospital, Pugliese Ciaccio Hospital , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"De Giacomo","sequence":"additional","affiliation":[{"name":"Dermatology Complex Unit, Dulbecco University Hospital, Pugliese Ciaccio Hospital , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026081712361776300_llag157-B1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/biom13071067","article-title":"Systemic photoprotection in melanoma and non-melanoma skin cancer","volume":"13","author":"Hyeraci","year":"2023","journal-title":"Biomolecules"},{"key":"2026081712361776300_llag157-B2","doi-asserted-by":"crossref","first-page":"2022-1","DOI":"10.7573\/dic.2022-1-2","article-title":"Benefit-risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma","volume":"11","author":"Garc\u00eda Ruiz","year":"2022","journal-title":"Drugs Context"},{"key":"2026081712361776300_llag157-B3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of 56 the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026081712361776300_llag157-B4","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3390\/cancers16122166","article-title":"Gorlin syndrome-associated basal cell carcinomas treated with vismodegib or sonidegib: a retrospective study","volume":"16","author":"Murgia","year":"2024","journal-title":"Cancers"},{"key":"2026081712361776300_llag157-B5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0579","article-title":"Evaluation of cemiplimab treatment duration: clinical outcomes in advanced CSCC","volume":"11","author":"Mallardo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026081712361776300_llag157-B6","doi-asserted-by":"crossref","first-page":"1111146","DOI":"10.3389\/fonc.2023.1111146","article-title":"The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: two case reports","volume":"13","author":"Colombo","year":"2023","journal-title":"Front Oncol"},{"key":"2026081712361776300_llag157-B7","doi-asserted-by":"crossref","first-page":"582866","DOI":"10.3389\/fonc.2020.582866","article-title":"Sonidegib for the treatment of advanced basal cell carcinoma","volume":"10","author":"Brancaccio","year":"2020","journal-title":"Front Oncol"},{"key":"2026081712361776300_llag157-B8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/hed.70056","article-title":"Safety and efficacy of vismodegib and sonidegib in advanced basal cell carcinoma of the head and neck: a systematic review and meta-analysis","volume":"48","author":"Doyle","year":"2026","journal-title":"Head Neck"},{"key":"2026081712361776300_llag157-B9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ad.2020.11.002","article-title":"Sonidegib in the treatment of locally advanced basal cell carcinoma","volume":"112","author":"Sanmart\u00edn","year":"2021","journal-title":"Actas Dermosifiliogr"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag157\/68157640\/llag157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/9\/1699\/68157640\/llag157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/9\/1699\/68157640\/llag157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:36:22Z","timestamp":1786984582000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/9\/1699\/8662347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,17]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag157","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,17]]}}}